News & Views
Call for Targets in Respiratory Disease
Jun 27 2016
Medical Charity MRC Technology (MRCT) and AstraZeneca are seeking academics with relevant epigenetics targets to collaborate with them to develop novel treatments for respiratory diseases, which affect millions of people every year.
Dr Justin Bryans, Director, Drug Discovery, at MRC Technology said: “By combining our expertise, we will generate more opportunities to translate early stage academic research into potential new therapies to benefit patients. We are aiming to accelerate the development of novel small molecule drugs that can specifically target epigenetic pathways involved in respiratory diseases.”
AstraZeneca and MRCT are particularly interested to hear from researchers studying epigenetic mechanisms involved in respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. In addition, they are also interested in epigenetic modulators acting in biological pathways relevant to respiratory, inflammatory or autoimmune disease, such as those involved in determining particular immune cell subsets or phenotypes (for example Tregs and T effector cells).
Drug discovery projects will be a multidisciplinary collaboration between academic scientists, AstraZeneca and MRCT. AstraZeneca and MRCT will provide proprietary small molecule collections, assay development and screening, medicinal chemistry, access to disease models for testing the molecules and project oversight.
Digital Edition
International Labmate 49.6 - Sept 2024
September 2024
Chromatography Articles - HPLC gradient validation using non-invasive flowmeters Mass Spectrometry & Spectroscopy Articles - From R&D to QC, making NMR accessible for everyone: Putting NMR...
View all digital editions
Events
Sep 11 2024 Bangkok, Thailand
Sep 11 2024 Bangkok, Thailand
Sep 11 2024 Singapore
Sep 18 2024 Lausanne, Switzerland
Sep 19 2024 Shanghai, China